Rank based on total amount | Funder | ChAdOx technology (to SG and AH only), £ (%) | Oxford–AstraZeneca vaccine, £ (%) | Total, £ (%) |
1 | Department of Health and Social Care | 0 (0.0) | 31 179 621 (89.3) | 31 179 621 (29.9) |
2 | European Commission | 23 545 255 (34.0) | 0 (0.0) | 23 545 255 (22.6) |
3 | Wellcome Trust | 14 144 606 (20.4) | 1 217 835 (3.5) | 15 362 440 (14.7) |
4 | Coalition for Epidemic Preparedness and Innovations | 12 098 260 (17.5) | 272 286 (0.8) | 12 370 546 (11.9) |
5 | Medical Research Council | 3 080 837 (4.4) | 2 174 848 (6.2) | 5 255 685 (5.0) |
6 | Foundation for National Institute of Health (US) | 5 729 292 (8.3) | 0 (0.0) | 5 729 292 (5.5) |
7 | Innovate UK | 2 403 678 (3.5) | 0 (0.0) | 2 403 678 (2.3) |
8 | European & Developing Countries Clinical Trials Partnership | 2 209 747 (3.2) | 0 (0) | 2 209 747 (2.1) |
9 | Bill and Melinda Gates Foundation | 1 595 006 (2.3) | 0 (0.0) | 1 595 006 (1.5) |
10–20 | Other | £4 506 697 (6.5%) | 68 106 (0.2) | 4 574 803 (4.4) |
Total | 69 313 379 | 34 912 696 | 104 226 076 |
Funders which contributed >£1 000 000 are shown.
AH, Professor Adrian Hill; ChAdOx, chimpanzee adenovirus-vectored vaccine; SG, Sarah Gilbert.